Comorbidities and its relation to performance status and estimated survival rate among cancer patients

Sankar, Veintramuthu; Parthasarathy, Rama; Mathew, S. Maurer; John, Subash; Kumar, Vignesh Kanda

doi:10.12991/jrp.2019.138

Cited by 1 publication

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with higher comorbidity scores (≥3) were more likely to have higher ECOG scores (1 and 2) than patients with low comorbidity scores (0-2) (p=0.007). This is consistent with previous studies showing that the ECOG score significantly increased in cancer patients with comorbidities in comparison with patients without comorbidities (30).…”

Section: Resultssupporting

confidence: 93%

“…The adjusted HRs for age (Age >65 vs. Age ≤65) and comorbidity (≥3 vs. 0-2) were 2.24 (95%CI=1.27-3.94, p=0.005) and 2.57 (95%CI=1.35-4.89, p=0.004), respectively. These findings are consistent with previous studies associating advanced age and presence of comorbidities with poor prognosis (30). Taken together, rs2151280 TT appears to be a potential prognostic factor (in addition to age and comorbidity score) for OS of leukemia patients after allo-HSCT.…”

Section: Resultssupporting

confidence: 92%

See 1 more Smart Citation

Association ofANRILPolymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation

et al. 2020

View full text Add to dashboard Cite

Background/Aim: Genetic variations of the noncoding RNA gene, ANRIL, have been associated with human diseases including cancer, type-2 diabetes, and atherosclerosis. In the present study, we investigated the potential associations of select ANRIL single nucleotide polymorphisms (SNPs) with overall survival and other clinical outcomes in adult patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients and Methods: Genomic DNA was extracted from whole blood samples from 103 adult patients with hematologic malignancies who had received allo-HSCT followed by oral tacrolimus therapy. The genotypes of four select ANRIL SNPs, rs564398, rs1063192, rs2151280, and rs2157719 were determined using qRT-PCRbased genotyping assays. Results: rs2151280 (C->T) in ANRIL was associated with worse overall survival in these patients (CT/CC vs. TT). Contrarily, rs2151280 and the other select ANRIL SNPs were not associated with death at Day-100 after transplantation, the incidence of graft-versus-host disease (GVHD), acute kidney injury (AKI), and neurotoxicity in the study cohort. Conclusion: rs2151280 represents a potential prognostic biomarker for overall survival in adult patients with hematologic malignancies after allo-HSCT. Chromosome 9p21 harbors the ARF-INK4 locus, which encodes three tumor suppressive proteins, p15 INK4B (P15), p16 INK4A (P16) and p14ARF (ARF) (1-5). P15 and P16 specifically inhibit cyclin D-dependent kinase 4 (CDK4)mediated phosphorylation of retinoblastoma protein (pRB), thus regulating cell cycle progression; ARF inhibits the ability of mouse double minute 2 homolog (MDM2) to suppress p53, and consequently promotes apoptosis or cell cycle arrest (4, 5). Recent studies have demonstrated that the non-coding RNA ANRIL (also designated as CDKN2BAS) is located adjacent to the INK4-ARF locus but is transcribed in the antisense direction with respect to p14ARF (6-9). ANRIL interacts with polycomb repressing complexes 1 and 2 (PRC1 and 2), and negatively regulates the transcription of the entire INK4-ARF locus (10-12). Emerging evidence has revealed that some single nucleotide polymorphisms (SNPs) in ANRIL are associated with susceptibility to the development of human diseases, including different types of cancer, type-2 diabetes and atherosclerosis (9, 13-26). Specifically, rs564398 has frequently been found in patients with leukemia and esophageal squamous cell carcinoma (ESCC). ANRIL rs2151280 has been associated with increased risk of developing lung cancer and basal cell carcinoma (BCC) while rs1063192 and rs2157719 have been correlated with glioma, brain cancer, and ESCC. Additionally, our previous study has demonstrated that 5707 This article is freely accessible online.

show abstract

Section: Resultssupporting

confidence: 93%

Section: Resultssupporting

confidence: 92%

Association ofANRILPolymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation

et al. 2020

View full text Add to dashboard Cite

show abstract

Comorbidities and its relation to performance status and estimated survival rate among cancer patients

Abstract: V, Rodrigues PA. Comorbidities and its relation to performance status and estimated survival rate among cancer patients.

Cited by 1 publication

References 22 publications

Association ofANRILPolymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation

Association ofANRILPolymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About